Nick Beije

Dr. Molewaterplein 40
Rotterdam, ZH 3015GD, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients.

Expression patterns of potential targets for antibody-directed therapy in metastatic castration-resistant prostate cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 01, 2026

Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.

Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer.

Journal: European urology focus

Published: December 03, 2025

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.

Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer.

Journal: JCI insight

Published: June 27, 2025

PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients.

PSA Secretion from Single Circulating Tumor Cells of Metastatic Castration-Naïve Prostate Cancer Patients.

Journal: Cancer research communications

Published: March 19, 2025

PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.

PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes.

Journal: European urology oncology

Published: February 13, 2025

Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.

Cell-free DNA aneuploidy score as a dynamic early response marker in prostate cancer.

Journal: Molecular oncology

Published: July 25, 2024

A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.

A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 16, 2024

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.

Journal: Cancer cell

Published: April 12, 2024

RNASEH2B loss and PARP inhibition in advanced prostate cancer.

RNASEH2B loss and PARP inhibition in advanced prostate cancer.

Journal: The Journal of clinical investigation

Published: December 08, 2023

PARP inhibitors for prostate cancer.

PARP inhibitors for prostate cancer.

Journal: Seminars in oncology

Published: September 07, 2023

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.

Journal: European urology

Published: March 17, 2023

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses.

Journal: Frontiers in oncology

Published: October 28, 2022

Showing 1-12 of 33

Last Updated: 09/26/2026